There’s no question that Tesla is becoming more famous by the day…
Tesla’s Model S has become a staple, must-own car among the wealthy, and even the used ones are selling for as much as $90,000 a pop. Even the Model 3 has booked more than 300,000 pre-orders within a week of its debut.
But another motor company is hitting its own records: Nikola Motor Company. Along with taking their name from the same inventor, Nikola Motor Company has taken in nearly $2.3 billion in pre-orders for its electric, Class 8 semi-truck, aptly nicknamed the Nikola One.
In addition to having near-zero emissions, the Nikola One is also able to outperform your typical diesel truck. Now, it’s not completely electric, but a gas-electric hybrid that can run at half the cost of current diesel trucks is impressive nonetheless.
Operating an electric truck — at half the cost — could potentially revolutionize the trucking industry.
For now, we’ll have to wait and see if that truly happens, but if it does, you can bet Nikola’s own name will rival Tesla in the future.
To continue reading more about Nikola and their electric trucks, click here.
Until next time,
Keith Kohl
Check us out on YouTube!A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.
For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.
Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.
